anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a randomized controlled trial comparing the use of linked color imaging (LCI) and magnifying blue laser imaging (BLI) versus standard white light for the detection of serrated lesions in the proximal colon (the colon proximal to the splenic flexure). The proximal colon has large intestine and many folds which will lead missing flat lesions. Recent studies have indicated that colonoscopy is more effective in preventing cancer in the left side of the colon than the right side of the colon. The reasons for this difference may be partly biologic, in that a special group of polyps known as serrated polyps, particularly sessile serrated adenomas, are located primarily proximal to the splenic flexure. These lesions are endoscopically subtle in that they are often flat, have the same color as the surrounding mucosa, and are hard to differentiate from normal mucosa. LCI makes red areas appear redder and white areas appear whiter. Thus, it is easier to recognize a slight difference in color of the mucosa. This study will test whether LCI will increase the detection of serrated lesions in a randomized controlled trial.
Bell's palsy is an alarming condition of rapid onset, which paralyzes half of the facial muscles. Kabat rehabilitation is a manual resistance technique that promotes a basic pattern of movement through facilitation, inhibition, and resistance of a group of muscles. It increases the functioning and power of facial muscles while Mime therapy results in immediate improvement of function and integrity of facial muscles. It also mitigates synkinesis in Bell's palsy. Both techniques are easy to apply. They are clinically important techniques that are easily understood by patients.
There have been reports of people getting out of bed after taking a sedative-hypnotic and driving their cars while not fully awake, often with no memory of the event. If a patient experiences such an episode, it should be reported to his or her doctor immediately, since “sleep-driving” can be dangerous. This behavior is more likely to occur when zolpidem tartrate tablets are taken with alcohol or other central nervous system depressants [see Warnings (5.3)]. Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with “sleep-driving”, patients usually do not remember these events.

Patients should be instructed NOT to take zolpidem tartrate tablets or other sedativehypnotics when drinking alcohol. In addition, patients should be advised to report all concomitant medications to the prescriber. Patients should be counseled to take zolpidem tartrate tablets right before they get in bed and only when they are able to stay in bed a full night (7-8 hours) before being active again. Patients should be instructed to report events such as sleep-driving and other complex behaviors immediately to the prescriber.
Golgi protein 73 (GP73) is implicated in key pathogenic processes, particularly those related to inflammation and fibrogenesis. In the last years, its measurement has emerged as a promising biomarker for detection of liver fibrosis (LF), a common consequence of chronic liver disease that can progress to cirrhosis and eventually hepatocellular carcinoma. GP73 concentrations in blood appear significantly increased in LF patients, correlating with disease severity, making this biomarker a possible non-invasive alternative for detecting and monitoring this condition regardless of etiology. Understanding the molecular mechanisms involving GP73 expression could also lead to new therapeutic strategies aimed at modulating its synthesis or function to prevent or reverse LF. Despite its clinical potential, GP73 as a LF biomarker faces several challenges. The lack of demonstrated comparability among different assays as well as the lack of knowledge of individual variability can make difficult the result interpretation. Further research is therefore needed focusing on robust clinical validation of GP73 as a LF biomarker. Addressing analytical, biological, and clinical limitations will be critical to exploiting its potential for improving detection and monitoring of advanced LF.
PURPOSE:To obtain a sustained release preparation capable of preventing side effects such as nausea while maintaining immediate effects, having extremely improved durability of action, by blending rapid released granules and sustained release granules containing emorfazone, respectively as a medicinal component. CONSTITUTION:1pt.wt. rapid released granules containing anti-inflammatory analgesic emorfazone: 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone are blended with 0.5-3pts.wt., preferably 1-2pts.wt. sustained release granules containing emorfazone. The rapid released granules are prepared by blending emorfazone with starch, excipient such as lactose and a binder such as hydroxypropyl cellulose or ethyl cellulose and the sustained release granules are prepared by blending emorfazone with a release controlling substance (e.g. methacrylic acid-methyl methacrylate copolymer or wax soluble at pH >=6) or the rapid released granules are coated with a sustained release substance film to prepare a sustained release preparation of emorfazone.
P swabs from the pediatric population \<=17 years, collected prospectively from pediatrics presenting with symptoms of respiratory illness. Tested within 72 hours of collection.
Brilliant pigment based on metal flake substrate with several coatings has (A) a first coating of SiO2 and/or (hydrated) Al2O3; (B) a second coating of metal and/or metal oxide without selective absorption; and (C) opt. a third coating of metal oxide, which is colourless or has selective absorption. Coating (A) is applied by (a) a wet chemical method, involving hydrolytic decomposition of organic Si and/or Al cpds., in which the organic gps. are bound to the metal by O atoms, in the presence of an organic solvent for these cpds., and opt. drying. The application of coating (B) involves (b1) coating with metal by gas phase decomposition of volatile metal cps. in an inert atmos. or (b2) electroless wet chemical plating and opt. drying or (b3) coating with metal oxide by gas phase decomposition of volatile metal cpds. in the presence of O2 and/or water vapour. If necessary, coating (C) is applied by method (b3) or (a), using suitable metal cpds. Also claimed are pigment mixts. and methods for producing the pigments and SiO2-coated metal flake substrates.
Patients receive cyclophosphamide PO and IV, pentostatin IV, anti-thymocyte globulin IV and undergo CD4+ T-cell depleted haploHCT on study. Patients also undergo bone marrow aspirate, bone marrow biopsy, and collection of blood samples at screening and follow-up.
A newborn baby born at 34 weeks and 5 days gestation was admitted for prematurity, dysmorphic features and congenital heart defects. Antenatal scan at 21 weeks showed a large-for-gestational-age foetus with a large abdominal circumference and liver, ventricular septal defect, right prominent renal pelvis and echogenic bowel. Antenatal genetic tests for overgrowth syndromes were negative. The mother had early onset pre-eclampsia. After birth, an overgrowth syndrome was still suspected despite the baby having normal birth parameters. Raw data of the trio whole exome sequencing from the amniocentesis sample were manually inspected. Hemizygous exon 7 deletion in the GPC3 gene was found, and a postnatal diagnosis of Simpson-Golabi-Behmel syndrome, a rare overgrowth syndrome, was made. This case report discusses the significance of antenatal findings, an atypical presentation of a rare syndrome and the obstacles of diagnostic genetic testing.
BACKGROUND: The efficacy of injections of mesenchymal stem cells (MSC) for anal fistula treatment may be impaired by the persistence of stools passing into the fistula, causing bacterial contamination and a local inflammatory reaction. We aimed to compare remission rates between patients treated by MSC injection with simple sutures and those treated with a rectal advancement flap.
METHODS: This single-center prospective study compared the first patients who underwent internal opening closure with sutures with the subsequent patients treated with a flap. Complete clinical remission was defined as complete closure of the external opening(s) without pain or discharge, and complete radiological remission was defined as a Magnifi-CD score of 0.
RESULTS: We compared the first 42 patients who had sutures with the 20 subsequent patients who had an advancement flap. The median follow-up was 15.5 [8.8-24.9] months. The cumulative incidence of complete clinical response at M12 was 53.8% [38.1-69.6%] in the suture group versus 93.3% [77.4-100.0] in the flap group (p < 0.001). The Magnifi-CD score was 0 for 41.7% [25.5-59.2%]) of patients treated with sutures versus 72.7% [39.0-63.9%]) of patients treated with a flap (p = 0.093). Anal incontinence score did not differ between the two groups. Practicing an advancement flap was the only significant factor associated with complete clinical remission over time (adjusted HR [95% CI] of 2.6 [1.4-4.9], p = 0.003).
CONCLUSIONS: Complete clinical remission rates following MSC injection are significantly higher after closure of the internal opening with a rectal flap than after closure with sutures, without consequences on anal continence.
Participants of this group are able to access the treatment program after 7 weeks of waiting period. After this waiting period of 7 weeks, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (Online Computerized Program group or Bibliotherapy group).
BACKGROUND: While inflammatory and immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in peripheral blood are extensively described, responses at the upper respiratory mucosal site of initial infection are relatively poorly defined. We sought to identify mucosal cytokine/chemokine signatures that distinguished coronavirus disease 2019 (COVID-19) severity categories, and relate these to disease progression and peripheral inflammation.
METHODS: We measured 35 cytokines and chemokines in nasal samples from 274 patients hospitalized with COVID-19. Analysis considered the timing of sampling during disease, as either the early (0-5 days after symptom onset) or late (6-20 days after symptom onset) phase.
RESULTS: Patients that survived severe COVID-19 showed interferon (IFN)-dominated mucosal immune responses (IFN-γ, CXCL10, and CXCL13) early in infection. These early mucosal responses were absent in patients who would progress to fatal disease despite equivalent SARS-CoV-2 viral load. Mucosal inflammation in later disease was dominated by interleukin 2 (IL-2), IL-10, IFN-γ, and IL-12p70, which scaled with severity but did not differentiate patients who would survive or succumb to disease. Cytokines and chemokines in the mucosa showed distinctions from responses evident in the peripheral blood, particularly during fatal disease.
CONCLUSIONS: Defective early mucosal antiviral responses anticipate fatal COVID-19 but are not associated with viral load. Early mucosal immune responses may define the trajectory of severe COVID-19.
<P>PROBLEM TO BE SOLVED: To provide an agent for preventing or treating itching skin diseases, which inhibits itches accompanied by itching skin diseases, such as atopic dermatitis, hives, contact dermatitis, psoriasis vulgaris, xeroderma, and prurigo, especially an agent for preventing or treating the atopic dermatitis, and is safe.  <P>SOLUTION: It has been found that lactoferrin inhibits peripheral sensory nerve elongation caused by making a nerve growth factor to act on PC12 cells. The lactoferrin exhibits an effect for treating and preventing the pruritus of NC mouse which is a model animal of the atopic dermatitis. It is also found that an effect for clearly improving the skin symptoms of a patient in a therapeutic experiment performed under the agreement of the patient suffering from the atopic dermatitis has been shown. Namely, the composition for the skin safely and quickly inhibits itches accompanied by itching skin diseases such as intractable atopic dermatitis, hives, contact dermatitis, psoriasis vulgaris, xeroderma, and prurigo. Thereby, the composition for the skin, containing the lactoferrin as an active ingredient can safely treat and prevent the skin diseases accompanied by an intractable itching sense, including the atopic dermatitis.  <P>COPYRIGHT: (C)2011,JPO&INPIT
OBJECTIVE: To assess the economic burden of neuromyelitis optica spectrum disorder (NMOSD) in the Colombian context.
METHODS: Analyses were conducted from a societal perspective using the prevalence-based approach. Costs were expressed in 2022 US dollars (1 USD = $3,914.46 COP). Direct medical costs were assessed from a bottom-up approach. Indirect costs included loss of productivity of the patient and their caregivers. The economic burden of NMOSD in Colombia was estimated as the sum of direct and indirect costs.
RESULTS: The direct cost of treating a patient with NMOSD was USD$ 8,149.74 per year. When projecting costs nationwide, NMOSD would cost USD$ 7.2 million per year. Of these costs, 53.5% would be attributed to relapses and 34.4% to pharmacological therapy. Indirect costs potentially attributed to NMOSD in Colombia were estimated at USD$ 1.5 million per year per cohort. Of these, 78% are attributable to loss of patient productivity, mainly due to reduced access to the labor market and premature mortality.
CONCLUSIONS: The NMOSD has a representative economic burden at the patient level, with direct costs, particularly related to relapses and medicines, being the main component of total costs. These findings are useful evidence that requires attention from public policymakers in Colombia.
Participants begin with a 4 week lead-in after screening to determine the frequency and severity of vertigo they are experiencing. Participants continue to track their vertigo episodes throughout the study. At Visit 2, if eligible, participants begin the titration of lamotrigine or matching placebo. Participants are on the full dose of lamotrigine/placebo for 8 weeks, and then begin taking bupropion or matching placebo along with lamotrigine or matching placebo for 12 weeks. At Week 27, participants are tapered off lamotrigine/placebo and stop taking bupropion/placebo. Participants have an in-person visit approximately once a month over 9 months.
A method of providing halotherapy to the upper portion of the lower respiratory tract includes the steps of operating a dispenser and inhaling. The dispenser contains a dry sodium chloride powder. The user operates the dispenser to release a dosage of the powder for inhalation when the dispenser is aimed into the user's mouth. The user then inhales the dosage of powder through the mouth. Because the powder has a particle size range enabling the powder to target the upper portion of the lower respiratory tract without entering the user's lungs, the dosage of the dry powder provides a concentration at the upper portion sufficient to provide effective halotherapy. The preferred particle size range is from about 5 microns to about 20 microns. The preferred dosage is about 3 milligrams of powder.
Recent studies show that CT-optimal touch, gentle slow stroking of the skin, can reduce pain. However, much is unknown regarding the factors influencing its pain-ameliorating effect, such as tactile attention and touch application site. The current study investigates in 36 healthy individuals, whether CT-optimal touch can reduce temporal summation of second pain (TSSP) compared to CT non-optimal touch and tapping the skin. TSSP refers to activation of the C-nociceptors; by stimulating these fibers a burning and/or tingling sensation can be elicited. All participants underwent three conditions on both the contralateral and ipsilateral side of pain induction. The results show that tapping the skin did not reduce TSSP, meaning that pain reduction through touch cannot be explained by tactile attention effects. CT non-optimal touch only reduced TSSP when applied on the ipsilateral side. Importantly, CT-optimal touch effectively reduced TSSP when applied on the contralateral or ipsilateral side. Furthermore, CT-optimal touch was more effective in reducing TSSP compared to CT non-optimal touch and Tapping. This study shows that that CT-optimal touch can reduce TSSP and this effect appears to be independent of touch application site, which is highly relevant for implementing CT-optimal touch as a treatment.
Inflammatory cytokines, including interleukin 6 (IL6), are associated with ion channel remodeling and enhance the propensity to alterations in cardiac rhythm generation and propagation, in which the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels play a crucial role. Hence, we investigated the consequences of exposure to IL6 on HCN channels in cell models and human atrial biopsies. In murine atrial HL1 cells and in cardiomyocytes derived from human induced pluripotent stem cells (hiPS-CMs), IL6 elicited STAT3 phosphorylation, a receptor-mediated downstream signaling. Downregulation of HCN1,2,4 by IL6 was observed after 24-48 h; in hiPS-CMs, this effect was reverted by 24 h of application of tocilizumab, a human IL6 receptor antagonist. In parallel, hiPS-CM action potentials (APs) showed a reduced spontaneous frequency. Moreover, we assessed IL6 and HCN expression in dilated left atrial samples from patients with mitral valve disease, an AF-prone condition. IL6 levels were increased in dilated atria compared to controls and positively correlated with echocardiographic atrial dimensions. Interestingly, the highest IL6 transcript levels and the lowest HCN4 and HCN2 expression were in these samples. In conclusion, our data uncovered a novel link between IL6 and cardiac HCN channels, potentially contributing to atrial electrical disturbances and a higher risk of dysrhythmias in conditions with elevated IL6 levels.
Paricalcitol Injection is available in 2 mcg/mL single dose vials (NDC 0143-9625-25), 5 mcg/mL single dose vials (NDC 0143-9624-25) and 10 mcg/2 mL (5 mcg/mL) multiple dose vials (NDC 0143-9596-25) in cartons of 25 vials.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze. After initial vial use, the contents of the multiple dose vial remain stable up to seven days when stored at controlled room temperature. Discard unused portion of the single dose vial.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
PURPOSE: The aim of this study was to investigate the risks and outcomes of patients with long-term oral anticoagulation (OAC) undergoing spine surgery.
METHODS: All patients on long-term OAC who underwent spine surgery between 01/2005 and 06/2015 were included. Data were prospectively collected within our in-house Spine Surgery registry and retrospectively supplemented with patient chart and administrative database information. A 1:1 propensity score-matched group of patients without OAC from the same time interval served as control. Primary outcomes were post-operative bleeding, wound complications and thromboembolic events up to 90 days post-surgery. Secondary outcomes included intraoperative blood loss, length of hospital stay, death and 3-month post-operative patient-rated outcomes.
RESULTS: In comparison with the control group, patients with OAC (n = 332) had a 3.4-fold (95%CI 1.3-9.0) higher risk for post-operative bleeding, whereas the risks for wound complications and thromboembolic events were comparable between groups. The higher bleeding risk was driven by a higher rate of extraspinal haematomas (3.3% vs. 0.6%; p = 0.001), while there was no difference in epidural haematomas and haematoma evacuations. Risk factors for adverse events among patients with OAC were mechanical heart valves, posterior neck surgery, blood loss > 1000 mL, age, female sex, BMI > 30 kg/m2 and post-operative PTT levels. At 3-month follow-up, most patients reported favourable outcomes with no difference between groups.
CONCLUSION: Although OAC patients have a higher risk for complications after spine surgery, the risk for major events is low and patients benefit similarly from surgery.
Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
PURPOSE:To obtain a poultice gelatinizable uniformly at an arbitrary rate of crosslinking, and having excellent age stability, by crosslinking a water-soluble polymer with a complexing agent and two or more polyvalent matellic salts capable of reacting with said complexing agent and giving respective complex salts having different stability constants from each other. CONSTITUTION:A water-soluble polymer such as gelatin, polyacrylic acid PVA, gum arabic, etc. is swollen or dissolved in water (about 10-60% of the whole poultice). A polyvalent metallic salt (preferably a slightly soluble or hardly soluble salt) capable of forming a complex salt having high stability constant (pK) is added to the solution, and then the mixture is added with a complex of (a) a polyvalent metallic salt forming a complex salt having lower pK than the above salt and (b) a complexing agent (e.g. EDTA, nitrilotriacetic acid, etc.). The crosslinking reaction takes place by the free polyvalent metallic ion produced by the metallic ion exchange in the complex. The amount of the polyvalent metallic salt having high pK is 0.5-5 equivalent, especially 0.8-1.5 equivalent, and that of the salt having low pK value is 0.2-20 equivalent, especially 0.8-5 equivalent, per 1 equivalent of the complexing agent.
Aqueous solutions of partial esters of polybasic organic acids and steroid alcohols, particularly cholesterol, prednisone, prednisolone, cortisone, hydrocortisone and hexamethasone, are stabilized by the addition of ethylenediaminetetracetic acid and/or khellin-carboxylic acid, and an alkanolamine, e.g. monoethanolamine, which is present in amount which gives the solution a pH of 7 to 8.  The polybasic acid components of the esters include di- and tricarboxylic acids, such as maleic, fumaric, succinic, adipic, malic and citric acids, and acids containing one or more phosphonic or sulphonic acid groups, e.g. m-sulphobenzoic acid.ALSO:Stable aqueous solutions of steroid esters suitable for use against ageing, arteriosclerosis and vaso-dilations comprise a partial ester of a polybaric organic acid and a steroid alcohol, an alkanolamine, e.g. monoethanolamine, and a stabilizer selected from ethylenediamine tetra-acetic acid and khellin-carboxylic acid, the alkanol-amine being present in an amount which gives the solution a pH of 7 to 8.  Steroids specified are cholesterol, prednisone, prednisolone, cortisone, hydrocortisone, and dexamethasone.  Poly basic acids include di- and tri-carboxylic acids, such as maleic, fumaric, succinic, adipic, malic and citric acids, and acids containing one or more phosphonic or sulphonic acid groups, e.g. m-sulphobenzoic acid.
Participants will attend two laboratory visits and complete a 3-week intervention, which consists of interactive parent-child activities (\~45 min of interactive activities/week) that pair tasting an assigned target vegetable with positive parent-child interactions. Positive interactions will be promoted via positive parenting prompts embedded in the activity instructions (e.g., prompts promoting child-directed play).